Details of the Drug

General Information of Drug (ID: DMDK7T9)

Drug Name

SBC-102

Synonyms

Sebelipase alfa; Enzyme replacement therapy (protein recombinant, lysosomal acid lipase deficiency), Synageva BioPharma

Indication

Disease Entry	ICD 11	Status	REF
Enzyme deficiency	5C51-5C57	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

A16AB14: SBC-102

A16AB: Enzymes

A16A: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

A16: OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

A: ALIMENTARY TRACT AND METABOLISM

Sequence

>Sebelipase alfa protein sequence
SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPV
VFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWA
FSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALG
PVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLC
FLLCGFNERNLNMSRVDVYTTHSPAGTSVQNMLHWSQAVKFQKFQAFDWGSSAKNYFHYN
QSYPPTYNVKDMLVPTAVWSGGHDWLADVYDVNILLTQITNLVFHESIPEWEHLDFIWGL
DAPWRLYNKIINLMRKYQ

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 942 mcgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 490 mcg/L [2]
Clearance: The clearance of drug is 31.1-38.2 L/h [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 5.4 - 6.6 minutes [2]
Metabolism: The drug is metabolized via the catabolism to smaller peptides and amino acids []
Vd: The volume of distribution (Vd) of drug is 3.6 L [2]

Cross-matching ID

UNII: K4YTU42T8G
DrugBank ID: DB11563
TTD ID: D0CH4A

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysosomal acid lipase (LIPA)	TTS8T1M	LICH_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01757184) A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy).U.S. National Institutes of Health.
2	FDA Approved Drug Products: Kanuma (sebelipase alfa) for intravenous injection
3	A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20.